Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
Status:
Suspended
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, two-stage trial with the goal of evaluating up to 100 subjects. This
trial will be performed to initiate identification of a safe and effective dose of
twice-weekly, subcutaneous rNAPc2 for the second-line treatment of metastatic colorectal
carcinoma in combination with contemporary 5-FU-based chemotherapy.